• Follow
  • Follow
  • Menu Item

Log in

Start free trial
  • Reports
    • Diagnostic Testing & Emerging Technologies
    • Lab Compliance Advisor
    • Laboratory Industry Report
    • National Lab Reporter
  • Articles
    • Diagnostic Testing and Emerging Technologies
      • DTC-dtet
      • Earnings-dtet
      • Emerging Tests-dtet
      • FDA-dtet
      • G2 Insider-dtet
    • Lab Compliance Advisor
      • Accreditation-lca
      • Brief Your CEO-lca
      • CLIA-lca
      • CMS-lca
      • Coding-lca
      • Compliance Corner-lca
      • Compliance Guidance-lca
      • Compliance Officers-lca
      • Compliance Perspectives-lca
      • Compliance Plans-lca
      • Compliance-lca
      • DOJ-lca
      • Employment-lca
      • Enforcement-lca
      • False Claims-lca
      • FDA-lca
    • Laboratory Industry Report
      • Capital-lir
      • CMS-lir
      • Deals-lir
      • Dx Pipeline-lir
      • Earnings-lir
      • Enforcement-lir
      • FDA-lir
      • Fee Schedules-lir
      • Funding-lir
    • National Lab Reporter
      • Guidelines at a Glance-nir
      • Health care reform-nir
      • HIPAA-nir
      • Labs in Court-nir
      • Legislation-nir
      • News-nir
      • OIG-nir
      • Reimbursement-nir
      • Safety-nir
  • News
  • Industry Perspectives
  • Webinars
  • Store

Diagnostic Testing and Emerging Technologies

LAB COMPLIANCE ADVISOR

LABORATORY INDUSTRY REPORT

NATIONAL LAB REPORTER

M&A & Strategic Deals: Dealmaking Shows New Signs of Life but FTC Scrutiny Casts a Dark Shadow

M&A & Strategic Deals: Dealmaking Shows New Signs of Life but FTC Scrutiny Casts a Dark Shadow

by Glenn S. Demby | Jun 1, 2023 | Industry Buzz-lir, Laboratory Industry Report

After a significant lull, M&As in the lab diagnostics space heated up in May, with several key deals announced.

This content is for Paid Members only.
Login Register
Preparing for or Considering Sale: The Anatomy of a Deal and Maximizing Your Opportunity

Preparing for or Considering Sale: The Anatomy of a Deal and Maximizing Your Opportunity

by G2 Intelligence Staff | May 31, 2023 | OLP, Webinars, webinars free

This panel will help laboratory owners make decisions now to be better positioned in the future for a potential sale.

Quest Expands into MRD Liquid Biopsy with Haystack Oncology Buy

Quest Expands into MRD Liquid Biopsy with Haystack Oncology Buy

by Glenn S. Demby | May 10, 2023 | News

The acquisition of the Johns Hopkins spin out and its liquid biopsy ctDNA test will significantly strengthen Quest’s oncology offerings.

Pfizer Acquires Lucira Health for $36.4 Million in Bankruptcy Auction

Pfizer Acquires Lucira Health for $36.4 Million in Bankruptcy Auction

by Glenn S. Demby | May 9, 2023 | News

Lucira has fallen on hard times since it secured the first FDA EUA for an at-home COVID-19 test in November 2020.

Hostile Regulatory Environment Further Chills Diagnostics Market

Hostile Regulatory Environment Further Chills Diagnostics Market

by Glenn S. Demby | May 4, 2023 | Industry Buzz-lir, Laboratory Industry Report

The biggest story in M&A dealmaking continues to be the deal that’s being undone—Illumina’s acquisition of GRAIL.

This content is for Paid Members only.
Login Register
« Older Entries

Log In


Join Now | Lost Password?

  • Follow
  • Follow
  • Homepage
  • FAQ
  • About Us
  • G2 Intelligence Team
  • Contact Us
  • Privacy Policy
  • Terms
Copyright © 2023 G2Intelligence.com